Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease

[1]  M. Matsuda,et al.  Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. , 2005, Science.

[2]  W. Hanif,et al.  Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males , 2005, Diabetologia.

[3]  Y. Matsuzawa.  Adipocytokines and metabolic syndrome. , 2005, Seminars in vascular medicine.

[4]  S. Kihara,et al.  Adiponectin-mediated modulation of hypertrophic signals in the heart , 2004, Nature Medicine.

[5]  H. Lodish,et al.  T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Nader Rifai,et al.  Plasma adiponectin levels and risk of myocardial infarction in men. , 2004, JAMA.

[7]  T. Ogihara,et al.  Hypoadiponectinemia Is an Independent Risk Factor for Hypertension , 2004, Hypertension.

[8]  S. Kihara,et al.  Adiponectin Specifically Increased Tissue Inhibitor of Metalloproteinase-1 Through Interleukin-10 Expression in Human Macrophages , 2004, Circulation.

[9]  NoriyukiOuchi,et al.  Selective Suppression of Endothelial Cell Apoptosis by the High Molecular Weight Form of Adiponectin , 2004 .

[10]  S. Kihara,et al.  Selective Suppression of Endothelial Cell Apoptosis by the High Molecular Weight Form of Adiponectin , 2004, Circulation research.

[11]  S. Kihara,et al.  Adiponectin and Metabolic Syndrome , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[12]  B. Fagerberg,et al.  Low adipocyte-derived plasma protein adiponectin concentrations are associated with the metabolic syndrome and small dense low-density lipoprotein particles: atherosclerosis and insulin resistance study. , 2003, Metabolism: clinical and experimental.

[13]  T. Ogihara,et al.  Association of Hypoadiponectinemia With Impaired Vasoreactivity , 2003, Hypertension.

[14]  Philippe Froguel,et al.  Cloning of adiponectin receptors that mediate antidiabetic metabolic effects , 2003, Nature.

[15]  S. Kihara,et al.  Association of Hypoadiponectinemia With Coronary Artery Disease in Men , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[16]  H. Lodish,et al.  Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl–CoA carboxylase inhibition and AMP-activated protein kinase activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[18]  C. Zoccali,et al.  Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. , 2002, Journal of the American Society of Nephrology : JASN.

[19]  M. Matsuda,et al.  Role of Adiponectin in Preventing Vascular Stenosis , 2002, The Journal of Biological Chemistry.

[20]  Jonathan Krakoff,et al.  Adiponectin and development of type 2 diabetes in the Pima Indian population , 2002, The Lancet.

[21]  M. Matsuda,et al.  Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. , 2002, Diabetes.

[22]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein Adiponectin Acts as a Platelet-Derived Growth Factor-BB–Binding Protein and Regulates Growth Factor–Induced Common Postreceptor Signal in Vascular Smooth Muscle Cell , 2002, Circulation.

[23]  M. Matsuda,et al.  Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 , 2002, Nature Medicine.

[24]  C. Bogardus,et al.  Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. , 2002, Diabetes.

[25]  M. Matsuda,et al.  Increased plasma HB-EGF associated with obesity and coronary artery disease. , 2002, Biochemical and biophysical research communications.

[26]  M. Matsuda,et al.  Small Heterodimer Partner, an Orphan Nuclear Receptor, Augments Peroxisome Proliferator-activated Receptor γ Transactivation* , 2002, The Journal of Biological Chemistry.

[27]  S. Kihara,et al.  Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[28]  T. Funahashi,et al.  Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. , 2001, Biochemical and biophysical research communications.

[29]  M. Matsuda,et al.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. , 2001, Diabetes.

[30]  Goutham Rao,et al.  Insulin resistance syndrome. , 2001, American family physician.

[31]  S. Kihara,et al.  Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Receptor Expression in Human Monocyte-Derived Macrophages , 2001, Circulation.

[32]  NoriyukiOuchi,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[33]  S. Kihara,et al.  Adiponectin, an Adipocyte-Derived Plasma Protein, Inhibits Endothelial NF-&kgr;B Signaling Through a cAMP-Dependent Pathway , 2000, Circulation.

[34]  T Nakamura,et al.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[35]  T Nakamura,et al.  An Adipocyte-Derived Plasma Protein, Adiponectin, Adheres to Injured Vascular Walls , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[36]  T Nakamura,et al.  Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. , 1999, Circulation.

[37]  T Nakamura,et al.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.

[38]  S. Kihara,et al.  Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. , 1999, Internal medicine.

[39]  K. Uysal,et al.  Protection from obesity-induced insulin resistance in mice lacking TNF-α function , 1997, Nature.

[40]  S. Kihara,et al.  Importance of intra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemia , 1997, International Journal of Obesity.

[41]  Y. Matsuzawa,et al.  Analysis of an expression profile of genes in the human adipose tissue. , 1997, Gene.

[42]  Y. Matsuzawa,et al.  Pathophysiology and molecular mechanisms of visceral fat syndrome: the Japanese experience. , 1997, Diabetes/metabolism reviews.

[43]  S. Kihara,et al.  Visceral fat accumulation as an important risk factor for obstructive sleep apnoea syndrome in obese subjects , 1997, Journal of internal medicine.

[44]  G. Reaven.  Banting lecture 1988 , 1997 .

[45]  S. Yamashita,et al.  Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.

[46]  B. Spiegelman,et al.  AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.

[47]  T. Funahashi,et al.  cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). , 1996, Biochemical and biophysical research communications.

[48]  G. Targher,et al.  Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[49]  Philipp E. Scherer,et al.  A Novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes (*) , 1995, The Journal of Biological Chemistry.

[50]  T Nakamura,et al.  Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. , 1994, Atherosclerosis.

[51]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[52]  Y. Matsuzawa,et al.  Close correlation of intra-abdominal fat accumulation to hypertension in obese women. , 1990, Hypertension.

[53]  Y. Matsuzawa,et al.  Correlation of intraabdominal fat accumulation and left ventricular performance in obesity. , 1989, The American journal of cardiology.

[54]  C. Bouchard,et al.  Role of Deep Abdominal Fat in the Association Between Regional Adipose Tissue Distribution and Glucose Tolerance in Obese Women , 1989, Diabetes.

[55]  N. Kaplan.  The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. , 1989, Archives of internal medicine.

[56]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[57]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[58]  Y. Matsuzawa,et al.  Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. , 1987, Metabolism: clinical and experimental.

[59]  A. Kissebah,et al.  Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin binding. Effects of obesity and body fat topography. , 1984, The Journal of clinical investigation.

[60]  P. Björntorp,et al.  Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. , 1984, British medical journal.

[61]  J. Vague,et al.  The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. , 1956, The American journal of clinical nutrition.